| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C5 |
| Uniprot No | P01031 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19 -1676aa |
| 氨基酸序列 | QEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C5重组蛋白的3篇参考文献示例(注：部分内容为模拟概括，实际文献需根据具体研究查询)：
---
1. **文献名称**：*Structural and functional characterization of recombinant human C5 protein*
**作者**：Smith AB, et al.
**摘要**：本研究通过哺乳动物表达系统成功表达并纯化重组人C5蛋白，解析其晶体结构，揭示了C5在补体激活途径中的构象变化机制，并验证了其与C5转化酶的特异性相互作用。
2. **文献名称**：*Development of a recombinant C5a antagonist for inflammatory disease therapy*
**作者**：Johnson CD, et al.
**摘要**：文章报道了一种重组C5a蛋白抑制剂的设计与功能研究，通过阻断C5a与受体的结合，显著减轻了小鼠模型中急性肺损伤的炎症反应，为补体靶向治疗提供新策略。
3. **文献名称**：*High-yield production of bioactive C5 in Pichia pastoris*
**作者**：Wang X, et al.
**摘要**：作者利用毕赤酵母表达系统优化重组C5蛋白的生产工艺，实现了高产量、高活性的C5制备，并通过质谱和功能实验证实其与天然C5的生物等效性，推动规模化应用。
---
**注意**：以上文献信息为示例，实际引用时请通过PubMed、Web of Science等数据库检索真实文献(关键词：C5 recombinant protein, complement system, C5a antagonist)。
C5 recombinant protein, a key component in the complement system, has garnered significant attention in therapeutic research and biopharmaceutical development. The complement system, a critical part of innate immunity, comprises over 30 proteins that orchestrate immune responses against pathogens, clear cellular debris, and modulate inflammation. Among these, complement component 5 (C5) plays a pivotal role as a convergence point for multiple complement activation pathways (classical, lectin, and alternative). Native C5 is a 190 kDa glycoprotein synthesized primarily in the liver, circulating in blood as a two-chain (α and β) precursor. Upon proteolytic cleavage by convertases, C5 releases the anaphylatoxin C5a and forms the C5b fragment, which initiates the membrane attack complex (MAC, C5b-9) to lyse pathogens or damaged cells.
Dysregulation of C5 activation is implicated in inflammatory, autoimmune, and degenerative diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration. This drove the development of recombinant C5 proteins and C5-targeted biologics. Recombinant C5 is produced using engineered cell lines (e.g., CHO or HEK293) to ensure consistent post-translational modifications and bioactivity. Its applications span structural studies, drug discovery, and as reference standards in diagnostic assays.
Therapeutic anti-C5 monoclonal antibodies (e.g., eculizumab, ravulizumab) leverage recombinant C5 for epitope characterization and mechanism validation. These inhibitors block C5 cleavage, preventing MAC formation and reducing complement-mediated tissue damage. Recent advances include long-acting C5 inhibitors and gene therapies aiming for sustained C5 suppression. However, challenges remain in balancing therapeutic efficacy with infection risks from complement inhibition. Ongoing research explores tissue-specific C5 modulation and novel recombinant variants with enhanced stability or modified interaction profiles, aiming to refine precision in complement-targeted therapies.
×
